PHAGE GP 1 TAB is a combination oral antidiabetic medication containing Metformin Hydrochloride (500 mg, sustained release) and Glimepiride (1 mg). Designed for effective management of Type 2 Diabetes Mellitus, it improves insulin sensitivity and stimulates pancreatic insulin release. Manufactured by Bluepill Express under international quality standards, this formulation offers reliable glycemic control with optimal patient compliance.

This product is manufactured under the Dr Precision label, ensuring GMP-compliant quality and precision formulation standards.

PHAGE GP 1 TAB is a dual-action oral antidiabetic formulation developed for effective and sustained glycemic control in patients suffering from Type 2 Diabetes Mellitus. This tablet combines two well-established antidiabetic agents: Metformin Hydrochloride 500 mg in a sustained-release form and Glimepiride 1 mg in an immediate-release form. This combination provides complementary mechanisms of action that target multiple aspects of glucose metabolism, making it ideal for patients who require combination therapy for optimal diabetes management.

Metformin, a biguanide class agent, primarily works by reducing hepatic glucose production, enhancing peripheral glucose uptake, and improving insulin sensitivity. It is especially beneficial in overweight and insulin-resistant individuals and is globally recognized as the first-line therapy in Type 2 diabetes. The sustained-release profile in PHAGE GP 1 TAB ensures a gradual and consistent release of Metformin throughout the day, thereby minimizing gastrointestinal side effects and improving patient adherence.

Glimepiride, a second-generation sulfonylurea, acts by stimulating insulin release from pancreatic beta cells. It has a rapid onset and long duration of action and is known for causing less weight gain and hypoglycemia compared to older sulfonylureas. The 1 mg dose in this combination is well-suited for patients initiating dual therapy or those with moderate glucose elevation despite Metformin monotherapy.

PHAGE GP 1 TAB is manufactured by Bluepill Express in advanced WHO-GMP, ISO, and HACCP-certified facilities that meet stringent international regulatory requirements. The formulation undergoes rigorous quality assurance processes including in-process checks, dissolution profiling, stability testing, and analytical validation. This ensures consistency, therapeutic reliability, and safety in every batch shipped for domestic or international use.

This tablet is indicated for adults with Type 2 Diabetes who do not achieve adequate glycemic control with diet, exercise, or monotherapy alone. It is frequently prescribed as a step-up treatment after Metformin monotherapy or as a maintenance therapy in stable patients requiring combined glycemic regulation. The fixed-dose combination improves compliance by reducing pill burden and offers synergistic benefits that help lower HbA1c more effectively than individual agents.

PHAGE GP 1 TAB is typically administered once daily with the first main meal to maximize its therapeutic benefits and reduce gastrointestinal discomfort. The pharmacokinetic compatibility between the sustained-release Metformin and fast-acting Glimepiride supports a consistent glucose-lowering effect throughout the day without excessive risk of hypoglycemia.

Bluepill Express offers PHAGE GP 1 TAB in customized packaging solutions such as alu-alu blisters or HDPE bottles, with private labeling, multilingual pack support, and all necessary documentation for international registrations including Certificate of Analysis, Batch Manufacturing Record, Stability Reports, and Dossiers. The product can be tailored to comply with the pharmacopeial and regulatory standards of importing countries.

The safety profile of PHAGE GP 1 TAB is well-established. Mild gastrointestinal side effects like nausea, flatulence, or diarrhea may occur initially, mainly due to Metformin. Glimepiride-associated risks like hypoglycemia are mitigated by the careful dosing strategy and the once-daily administration format. It is contraindicated in patients with severe renal impairment, hepatic dysfunction, or known sulfonylurea hypersensitivity.